| Revision as of 19:53, 30 November 2008 editNicke L (talk | contribs)Extended confirmed users3,125 editsm +sv:← Previous edit | Revision as of 16:41, 29 December 2008 edit undoZefryl (talk | contribs)148 edits multiple changes, see talk pageNext edit → | ||
| Line 1: | Line 1: | ||
| '''Noradrenergic and |
'''Noradrenergic and specific serotonergic antidepressants''' (abbreviated: '''NaSSAs''') are a relatively new class of ]s.<ref>{{cite journal |author=Kent J |title=SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression |journal=Lancet |volume=355 |issue=9207 |pages=911–8 |year=2000 |pmid=10752718 |doi=10.1016/S0140-6736(99)11381-3}}</ref> They are thought to work by blocking presynaptic ] that normally inhibit the release of the ]s ] (]) and ]. By releasing them from inhibitory control, NaSSAs act as ] for these neurotransmitters. NaSSAs are said to be ''specific'' serotonergic antidepressants since they have affinity for only certain serotonin receptors. ], for instance, has high affinity for the ] and ]s, but no significant affinity for the ] or ]s. | ||
| Examples of NaSSAs include: | Examples of NaSSAs include: | ||
Revision as of 16:41, 29 December 2008
Noradrenergic and specific serotonergic antidepressants (abbreviated: NaSSAs) are a relatively new class of antidepressants. They are thought to work by blocking presynaptic alpha-2 adrenergic receptors that normally inhibit the release of the neurotransmitters norepinephrine (noradrenaline) and serotonin. By releasing them from inhibitory control, NaSSAs act as agonists for these neurotransmitters. NaSSAs are said to be specific serotonergic antidepressants since they have affinity for only certain serotonin receptors. Mirtazapine, for instance, has high affinity for the 5-HT2 and 5-HT3 receptors, but no significant affinity for the 5-HT1A or 5-HT1B receptors.
Examples of NaSSAs include:
- Mirtazapine (Remeron, Zispin, Avanza, Norset, Remergil, Axit)
NaSSAs are said to have fewer side effects than tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) while being equally effective. In particular, it is said that the sexual dysfunction that is a relatively common side effect of SSRIs occurs significantly less often during treatment with Mirtazapine.
See also
References
- Kent J (2000). "SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression". Lancet. 355 (9207): 911–8. doi:10.1016/S0140-6736(99)11381-3. PMID 10752718.
- Fawcett J, Barkin R (1998). "Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression". J Affect Disord. 51 (3): 267–85. doi:10.1016/S0165-0327(98)00224-9. PMID 10333982. link
 | This medical treatment–related article is a stub. You can help Misplaced Pages by expanding it. |